Medexus Pharmaceuticals Inc.
MEDXF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $61 | $75 | $46 | $60 |
| - Cash | $9 | $9 | $24 | $8 |
| + Debt | $21 | $22 | $37 | $40 |
| Enterprise Value | $73 | $88 | $59 | $91 |
| Revenue | $25 | $25 | $25 | $30 |
| % Growth | 0.5% | -0.6% | -17.5% | – |
| Gross Profit | $14 | $14 | $12 | $15 |
| % Margin | 55.7% | 56% | 50.2% | 50.7% |
| EBITDA | $4 | $4 | $4 | $5 |
| % Margin | 14.2% | 18.1% | 14.9% | 15.4% |
| Net Income | -$0 | $1 | -$1 | $1 |
| % Margin | -1.3% | 2.1% | -2.2% | 2.4% |
| EPS Diluted | -0.01 | 0.016 | -0.02 | 0.03 |
| % Growth | -159.3% | 181.4% | -167% | – |
| Operating Cash Flow | $3 | $4 | $2 | $7 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $3 | $4 | $2 | $7 |